2021 Reasonable Consumer Quiz
See how you stack up.
Hello Fresh’s '17 Free Meals'
Here's how much you have to spend to get 17 "free" meals.
Deceptive Ad Trends to Be Wary of in 2022
Enter the metaverse.
TINA.org’s Ninth Year in Review
Here's what we accomplished in 2021 with your help.
Companies that Get Coal in 2021
Find out why New Balance, TikTok, Poland Spring and others make TINA.org's 2021 naughty list.
Heineken 0.0 – Cheers with No Alcohol. Now You Can.
Cheers or no cheers?
SlimFast’s ‘Clinically Proven’ Weight-Loss Claims
Recent inquiry takes aim at company's "clinically proven" weight-loss claims, with a somewhat surprising result.
Penny Stock Checklist
"Free” offer is apparently tied to a subscription that isn’t free.
‘A Little Gift’ from ‘ATT’
Be wary of messages from numbers you don’t recognize offering gifts.
LeafGuard: 'Stay Off the Ladder'
Don't bury that ladder in the garage just yet.
Deceptive Ads of 2021
Some bad ads from this year.
Worst False Ad Settlements of 2021
Class-action settlements leave consumers behind.
CATrends: Hidden Food Delivery Fees
Be wary of claims of free or low-cost delivery.
Opinion
The Polygraph
Posts from Bonnie Patten, our Executive Director
FTC to MLMs: You Lie, You Pay
The agency puts the MLM industry on notice.
Stay Connected
Our Legal Action
Beautycounter
TINA.org's investigation of MLM makeup company reveals ugly deceptive income claims. Read More >
Balance of Nature
TINA.org reports supplement maker for falsely claiming its "Fruits and Veggies" supplements can help prevent and treat the coronavirus. Read More >
Neutrogena-branded Sunscreen
Allegations: Failing to disclose sunscreens contain the carcinogen benzene
Walgreens Cough Medicines with DXM
Allegations: Misleadingly marketing medicines as “non-drowsy” when the active ingredient in them causes drowsiness
The true cost of Amazon’s low prices vox.com/recode/2283636…
Meta’s Oculus Unit Faces FTC-Led Probe of Competition Practices bloomberg.com/news/articles/…
Shkreli’s infamous 4,000% price hike gets him a lifetime pharma ban arstechnica.com/science/2022/0…
